<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635359</url>
  </required_header>
  <id_info>
    <org_study_id>BCX 120</org_study_id>
    <nct_id>NCT03635359</nct_id>
  </id_info>
  <brief_title>Automated Screen for Fetal Aneuploidy</brief_title>
  <acronym>FAST1</acronym>
  <official_title>Fluidic Automated Screening for Trisomy Study I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCeryx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brugmann University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Prince Alfred Hospital, Sydney, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital CUF Descobertas, Lisbon, Portugal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioCeryx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop and evaluate a blood test and automated microfluidic
      test platform for the prenatal screening of fetal aneuploidy.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 15, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of blood test to fetal karyotype</measure>
    <time_frame>21 months</time_frame>
    <description>Maternal plasma cell-free DNA will be analyzed to determine copy number of specific chromosomes and compared to the fetal karyotype as obtained through invasive diagnostic testing of the fetus.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Trisomy 21 and Other Fetal Aneuploidy</condition>
  <arm_group>
    <arm_group_label>positive for fetal aneuploidy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>negative for fetal aneuploidy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood test</intervention_name>
    <description>analysis of cell-free DNA in maternal plasma</description>
    <arm_group_label>negative for fetal aneuploidy</arm_group_label>
    <arm_group_label>positive for fetal aneuploidy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant with singleton or twin pregnancy and having and indicated physician prescribed
        prenatal diagnostic procedure.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is at least 18 years old and can provide informed consent;

          2. Subject has a viable singleton or twin pregnancy;

          3. Subject is confirmed to be at least 10 weeks, 0 days gestation at the time of the
             study blood draw;

          4. Subject is planning to undergo chorionic villus sampling and/or amniocentesis for the
             purpose of genetic analysis of the fetus because of a suspected fetal chromosomal
             anomaly based on cell-free DNA test results, standard serum screening result, or fetal
             ultrasound abnormality.

          5. OR the subject has already undergone chorionic villus sampling and/or amniocentesis
             and is known to have a fetus with a chromosomal abnormality confirmed by genetic
             analysis.

        Exclusion Criteria:

          1. Subject (the mother) has known aneuploidy;

          2. Subject is pregnant with more than two fetuses or has had sonographic evidence of
             three or more gestational sacs at any time during pregnancy;

          3. Subject has a fetal demise (including natural or elective reduction) identified prior
             to consent;

          4. Subject has history of malignancy treated with chemotherapy and/or major surgery, or
             bone marrow transplant.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Musci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioCeryx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital CUF Descobertas</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cl√≠nico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>August 14, 2018</last_update_submitted>
  <last_update_submitted_qc>August 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fetal</keyword>
  <keyword>screening test</keyword>
  <keyword>trisomy</keyword>
  <keyword>aneuploidy</keyword>
  <keyword>copy number variant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Aneuploidy</mesh_term>
    <mesh_term>Trisomy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

